NR4A1 and breast carcinoma: The peptides demonstrate preferential selectivity for breast cancer cells (25–95-fold vs. other cancer types), broad-spectrum activity against both hormone receptor-positive and triple-negative subtypes, and remarkable synergistic effects with standard chemotherapy that could revolutionize combination therapy approaches.